SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS

ABSTRACT OF THE DISCLOSURE

The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example $\alpha_v \beta_3$ and $\alpha_v \beta_5$ integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by $\alpha_v \beta_3$ and $\alpha_v \beta_5$ integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula:

where $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, D, X, W, a, m, n, i, j, k$ and v are defined herein.

A293-46.doc